Literature DB >> 10589983

Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes.

A Liendo1, G Visbal, M M Piras, R Piras, J A Urbina.   

Abstract

A detailed analysis of the endogenous sterols present in the clinically relevant intracellular (amastigote) stages of Trypanosoma cruzi, is presented. The parasites were grown in cultured Vero cells in the absence or presence of different sterol biosynthesis inhibitors, including the C14alpha demethylase inhibitor ketoconazole and two inhibitors of delta24(25)-sterol methyl transferase, 20 piperidin-2-yl-5alpha-pregnan-3beta-20-R-diol (22,26-azasterol) and 24-(R,S),25-epiminolanosterol. Amastigotes were isolated and purified from their host cells and neutral lipids were extracted, separated and analyzed by chromatographic and mass spectrometric methods. Control (untreated) amastigotes contained as main endogenous sterols 24-methyl-cholesta-7-en-3beta-ol (ergosta-7-en-3beta-ol) and its 24-ethyl analog, plus smaller amounts of their precursor, ergosta-7,24(28)dien-3beta-ol; these cells also contained cholesterol (up to 80% by weight of total sterols), probably derived from host cells. Amastigotes that proliferated in the presence of 10 nM ketoconazole (minimal inhibitory concentration, MIC) for 24 h had a sharply reduced content of endogenous 4-desmethyl sterols with a concomitant accumulation of 24-methyl-dihydrolanosterol and 24-methylene-dihydrolanosterol. On the other hand, amastigotes incubated during the same period of time with the two inhibitors of 24(25)-SMT at their respective MICs (100-300 nM) accumulated large amounts of C27 sterols whose structure suggested, in the case of 22,26-azasterol, that delta14 sterol reductase was also inhibited. Ketoconazole produced a dose-dependent reduction in the incorporation of [2-(14)C]-acetate into the parasite's endogenous C4-desmethyl sterols with an IC50 of 50 nM, indistinguishable from the value reported previously for the extracellular epimastigote form. Taken together, the results showed that amastigotes have a simpler sterol biosynthetic pathway than that previously described for epimastigotes, lacking both delta5 and delta22 reductases. They also suggest that the 100-fold higher potency of antifungal azoles as antiproliferative agents against amastigotes, when compared with epimastigotes, is most probably due to a smaller pool of endogenous sterols in the intracellular parasites.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589983     DOI: 10.1016/s0166-6851(99)00129-2

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  33 in total

1.  New aspects on lanosterol 14alpha-demethylase and cytochrome P450 evolution: lanosterol/cycloartenol diversification and lateral transfer.

Authors:  Tadeja Rezen; Natasa Debeljak; Dusan Kordis; Damjana Rozman
Journal:  J Mol Evol       Date:  2004-07       Impact factor: 2.395

Review 2.  Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).

Authors:  Galina I Lepesheva; Fernando Villalta; Michael R Waterman
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

3.  SQ109, a new drug lead for Chagas disease.

Authors:  Phercyles Veiga-Santos; Kai Li; Lilianne Lameira; Tecia Maria Ulisses de Carvalho; Guozhong Huang; Melina Galizzi; Na Shang; Qian Li; Dolores Gonzalez-Pacanowska; Vanessa Hernandez-Rodriguez; Gustavo Benaim; Rey-Ting Guo; Julio A Urbina; Roberto Docampo; Wanderley de Souza; Eric Oldfield
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

4.  Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast.

Authors:  Sabine Ottilie; Gregory M Goldgof; Claudia Magalhaes Calvet; Gareth K Jennings; Greg LaMonte; Jake Schenken; Edgar Vigil; Prianka Kumar; Laura-Isobel McCall; Eduardo Soares Constantino Lopes; Felicia Gunawan; Jennifer Yang; Yo Suzuki; Jair L Siqueira-Neto; James H McKerrow; Rommie E Amaro; Larissa M Podust; Jacob D Durrant; Elizabeth A Winzeler
Journal:  ACS Chem Biol       Date:  2016-12-23       Impact factor: 5.100

5.  Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.

Authors:  Frederick S Buckner; Julio A Urbina
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-12       Impact factor: 4.077

6.  A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

Authors:  Patricia S Doyle; Chiung-Kuang Chen; Jonathan B Johnston; Stephanie D Hopkins; Siegfried S F Leung; Matthew P Jacobson; Juan C Engel; James H McKerrow; Larissa M Podust
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

7.  Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis.

Authors:  Juliany C F Rodrigues; Márcia Attias; Carlos Rodriguez; Julio A Urbina; Wanderley de Souza
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis.

Authors:  Silvia Orenes Lorente; Juliany C F Rodrigues; Carmen Jiménez Jiménez; Miranda Joyce-Menekse; Carlos Rodrigues; Simon L Croft; Vanessa Yardley; Kate de Luca-Fradley; Luis M Ruiz-Pérez; Julio Urbina; Wanderley de Souza; Dolores González Pacanowska; Ian H Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects.

Authors:  Juliany Cola Fernandes Rodrigues; Juan Luis Concepcion; Carlos Rodrigues; Aura Caldera; Julio A Urbina; Wanderley de Souza
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

10.  Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs.

Authors:  Wanderley de Souza; Juliany Cola Fernandes Rodrigues
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.